MCB1 also mediates sorafenib/lenvatinib resistance by downregulating FGFR1 and VEGFR3 expression in a proteasome‐dependent manner and serves as a potential biomarker for individualized HCC therapy. The gene discussed is FLT4; the disease is hepatocellular carcinoma.